<div id="readability-page-1"><p>H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Sanara MedTech today and set a price target of $36.00.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Chen covers the Healthcare sector, focusing on stocks such as RegenXBio, Formycon AG, and Oculis Holding. According to TipRanks, Chen has an average return of <span>-4.3%</span> and a 41.32% success rate on recommended stocks. </p> <p>Currently, the analyst consensus on Sanara MedTech is a Moderate Buy with an average price target of $41.00.</p></div>

SMTI

<p>H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Sanara MedTech with a price target of $36.00. The analyst consensus on Sanara MedTech is a Moderate Buy with an average price target of $41.00.</p>

H.C. Wainwright Keeps Their Buy Rating on Sanara MedTech (SMTI)